Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

Novo Nordisk launches its weight-loss drug Wegovy in China after approval by local health authorities in June.

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.